SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xenova (XNVA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who started this subject10/8/2003 4:53:05 AM
From: nigel bates  Read Replies (1) of 173
 
Xenova Initiates Second Clinical Trial for Anti-Smoking Vaccine

SLOUGH, England, Oct. 8 /PRNewswire-FirstCall/ -- Xenova Group plc (Nasdaq: XNVA - News; London Stock Exchange: XEN - News) today announced that it has initiated a second clinical trial for TA-NIC, its therapeutic vaccine which is under development for the treatment of nicotine addiction.

This second Phase I study builds upon the findings of a previous Phase I trial which were announced in June 2002. The results of this first study, which was the first evaluation of an anti-nicotine vaccine in man, showed that the vaccine generated a specific anti-nicotine response and that it was safe and well tolerated both systemically and locally. The objective of the new Phase I trial is to further establish safety and tolerability, and to determine the vaccination dose and schedule required to induce the optimal anti-nicotine antibody response. Three different doses of the vaccine will be evaluated. The impact of vaccination on nicotine-induced changes in heart rate and skin temperature will also be monitored.

Approximately 60 smokers will be recruited into a double-blind, randomised, placebo-controlled study which will be run at a European clinical centre experienced in testing smoking related therapies. Results of this study will be used to design a Phase II trial that will assess the effect of vaccination with TA-NIC on tobacco consumption. This Phase II trial is expected to begin during the second half of 2004.

Commenting on this new trial David Oxlade, CEO of Xenova Group plc said, "TA-NIC offers the hope of substantial benefit to smokers wishing to quit their habit. With this new trial we will be directly assessing the impact of antibodies on the physiological effects of nicotine. It represents an important step forward in strengthening the concept of vaccination as a treatment for nicotine addiction."...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News